TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 376459
Drug: NAB 365
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NAB 365 (clenbuterol) administered at 30 micrograms b.i.d. for 3 days, then reduced to 20 micrograms b.i.d. for an average of 13 days.
Study: 376459
Drug: Salbutamol administered
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol administered at 4 mg t.i.d. for an average of 13 days.
Study: 25179260
Drug: VCD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCD treatment
Study: 23345050
Drug: Piperacillin/tazobactam (PIPC/TAZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (PIPC/TAZ, 13.5 g/day)
Study: 23345050
Drug: Meropenem (MEPM,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (MEPM, 1.5 g/day)
Study: 17932841
Drug: 1-day application
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day application of topical 0.5% levofloxacin
Study: 17932841
Drug: 3-day application
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day application of topical 0.5% levofloxacin
Study: 11175234
Drug: Nocturnal transtracheal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal transtracheal augmented ventilation (TTAV) at 10 L/min
Study: 11367663
Drug: Qingyu Jiuxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingyu Jiuxin Pills (QYJXP)
Study: 8154033
Drug: imipenem/cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipenem/cilastatin (500 mg)
Study: 8154033
Drug: placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (100 ml)
Study: 29316960
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) 150-300 mg twice daily for 8 weeks
Study: 29316960
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 400-800 mg three times daily for 8 weeks
Study: 22883608
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose 5-ALA (15 mg capsule)
Study: 22883608
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose 5-ALA (50 mg capsule)
Study: 22883608
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo capsule)
Study: 15459595
Drug: Amiodarone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (15 mg/kg IV over 24 hours followed by 200 mg orally 3 times per day for 7 days)
Study: 15459595
Drug: Sotalol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (80 mg orally 2 times per day for 7 days)
Study: 11174041
Drug: High-dose folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folic acid, vitamin B6, and vitamin B12 supplements
Study: 11174041
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of folic acid, vitamin B6, and vitamin B12 supplements
Study: 9253332
Drug: PTHrP (parathyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTHrP (parathyroid hormone-related peptide-(1-34))
Study: 8494580
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (0.14 mg/nostril b.i.d.)
Study: 8494580
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal aerosol (0.05 mg/nostril b.i.d.)
Study: 8494580
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray and Budesonide nasal aerosol
Study: 3320788
Drug: Carvedilol, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol, a new beta-adrenergic blocking agent with direct vasodilator activity, administered orally.
Study: 27282118
Drug: Enhanced treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment-as-usual (ETAU)
Study: 30085876
Drug: Enamel deproteinization,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel deproteinization, acid etching, bonding agent application, and pit & fissure sealant placement
Study: 27714541
Drug: Cabozantinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (100 mg daily during a 12-week lead-in stage)
Study: 24990101
Drug: Full portion
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full portion aerated drink (1,000 ml, 190 kcal)
Study: 24990101
Drug: Half portion
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half portion aerated drink (500 ml, 95 kcal)
Study: 24990101
Drug: Full portion
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full portion liquid drink (325 ml, 190 kcal)
Study: 24990101
Drug: Half portion
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half portion liquid drink (162 ml, 95 kcal)
Study: 18201301
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT‐A) injections into the submandibular and parotid glands; 25 units of BoNT‐A into each gland.
Study: 12082182
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received no treatment.
Study: 19619146
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg daily
Study: 9288699
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 0.625 mg daily
Study: 15989411
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg + CEE 0.625 mg daily
Study: 10494116
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 15 mg trospium chloride in 40 ml saline
Study: 10494116
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 30 mg trospium chloride in 40 ml saline
Study: 8702086
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (conjugated estrogens, 0.625 mg/d and medroxyprogesterone, 5 mg/d)
Study: 6751514
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery followed by cis-platinum containing combination chemotherapy
Study: 29017511
Drug: Mechanical wrist
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical wrist traction (12 treatments, twice a week for 6 weeks)
Study: 24368400
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg/day plus erlotinib 150 mg/day
Study: 20014909
Drug: Atomoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (40 mg/day)
Study: 14739125
Drug: Torcetrapib 10
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 10 mg daily
Study: 14739125
Drug: Torcetrapib 30
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 30 mg daily
Study: 14739125
Drug: Torcetrapib 60
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 60 mg daily
Study: 14739125
Drug: Torcetrapib 120
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 120 mg daily
Study: 14739125
Drug: Torcetrapib 120
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 120 mg twice daily
Study: 3113329
Drug: Cefadroxil (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil (75 children), given once daily
Study: 3113329
Drug: Phenoxymethyl penicillin
Normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethyl penicillin (75 children), given three times daily
Study: 31975475
Drug: Topical selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical selenium (Se)
Study: 28363480
Drug: 16 mg/day
Normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/day TRF-budesonide
Study: 28363480
Drug: 8 mg/day
Normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/day TRF-budesonide
Study: 24191330
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of flurbiprofen (tablet Flurso)
Study: 24191330
Drug: Branded product
Normalized name: Eagle Brand Medicated Oil Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded product of flurbiprofen (tablet Ansaid)
Study: 14747426
Drug: d‐MPH administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH administered in a fasting state
Study: 14747426
Drug: d‐MPH administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH administered after a high‐fat breakfast
Study: 14747426
Drug: d‐MPH administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH administered with food
Study: 12745746
Drug: 1.5% glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% glycine infusion at 0.5 ml/kg/min for 30 min
Study: 12745746
Drug: 3% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% mannitol infusion (control)
Study: 12745746
Drug: 1.5% glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% glycine infusion
Study: 8085509
Drug: Home Treatment
Normalized name: Home-brew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Treatment Team (HTT)
Study: 29488152
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg
Study: 24516103
Drug: Sitagliptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 200 mg
Study: 23881910
Drug: Maraviroc (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (7 days administration)
Study: 17909199
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + Chemotherapy
Study: 9777793
Drug: Tazarotene-UVB treatment
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene-UVB treatment (tazarotene 0.1% gel once daily for 2 weeks followed by tazarotene plus UVB therapy 3 times per week for 10 weeks)
Study: 4043476
Drug: UVB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB therapy alone
Study: 9777793
Drug: UVB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB therapy plus vehicle gel
Study: 7817163
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml (0.1 mg) fentanyl intravenously
Study: 7817163
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml saline intravenously
Study: 17649720
Drug: ATRA +
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA + chemotherapy
Study: 30056747
Drug: Melodic Intonation
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melodic Intonation Therapy (12 sessions over six weeks)
Study: 30056747
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control (no treatment initially)
Study: 23940216
Drug: cediranib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib (30 mg) monotherapy
Study: 23940216
Drug: cediranib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib (20 mg) plus lomustine (110 mg/m(2))
Study: 23940216
Drug: lomustine (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: lomustine (110 mg/m(2)) plus placebo
Study: 23940216
Drug: cediranib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib (30 mg) monotherapy and cediranib (20 mg) plus lomustine
Study: 16627149
Drug: Mail administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mail administration of SF-36 and Oxford Hip questionnaires
Study: 16627149
Drug: Interview administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interview administration of SF-36 and Oxford Hip questionnaires
Study: 8605789
Drug: Flumazenil (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (maximum of 1 mg in double-blind phase, up to 2.5 mg in open phase)
Study: 8605789
Drug: Flumazenil (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.7 +/- 0.3 mg)
Study: 1874931
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg elemental calcium/day
Study: 1874931
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg elemental calcium/day
Study: 1874931
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (both doses)
Study: 31371315
Drug: Low-dose dacarbazine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dacarbazine (DTIC) administered at 850 mg/m2 intravenously on days 1 and 28, and interferon‐alpha‐2b (IFN‐α‐2b) administered at 3 million units three times a week subcutaneously for 24 weeks beginning at week 9.
Study: 31371315
Drug: Low-dose dacarbazine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dacarbazine (DTIC) and interferon‐alpha‐2b (IFN‐α‐2b)
Study: 30149135
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri (2 × 10^8 CFU, twice daily during antibiotic treatment)
Study: 26455249
Drug: Counselling group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling group (written instruction + monthly counselling)
Study: 21545190
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection of methylprednisolone acetate 40 mg/mL with 0.8 mL lidocaine plus injection of 1 mL hyaluronic acid 0.8% 10 days later (n=15; group A)
Study: 16634495
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of implants (< or = 14 days postimplantation)
Study: 16634495
Drug: Standard loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard loading of implants (3 to 4 months postimplantation)
Study: 8695094
Drug: Epidural PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural PCA (EPCA) with sufentanil: 0.3 microgram/kg bolus followed by 8 micrograms/hr infusion plus epidural PCA boluses of 4 micrograms every 6 min as needed
Study: 8695094
Drug: i.v. PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. PCA with sufentanil: 0.3 microgram/kg bolus followed by 8 micrograms/hr infusion plus IV PCA boluses of 4 micrograms every 6 min as needed
Study: 8695094
Drug: i.v. PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. PCA with morphine: 0.1 mg/kg bolus followed by 0.5 mg/hr infusion plus i.v. PCA boluses of 1 mg every 6 min as needed
Study: 29432857
Drug: intensive antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensive antiretroviral treatment strategy
Study: 29432857
Drug: standard antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard antiretroviral treatment strategy
Study: 29432857
Drug: interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: interruption of treatment
Study: 29432857
Drug: continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuation of treatment
Study: 22906371
Drug: Bone-anchored maxillary
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-anchored maxillary expander (BAME) treatment
Study: 21046863
Drug: Ten minute
Normalized name: Tagetes minuta flower oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten minute medication review by a general practitioner
Study: 17582921
Drug: Human papillomavirus
Normalized name: human papillomavirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human papillomavirus vaccine
Study: 10470696
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin, methotrexate, and vinblastine, with folinic acid rescue)
Study: 27663567
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (control)
Study: 7782463
Drug: Exner administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exner administration
Study: 7782463
Drug: first Exner
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: first Exner administration
Study: 7782463
Drug: Rapaport administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapaport administration
Study: 2184796
Drug: High-dose levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose levothyroxine sodium added to a stable regimen of medications
Study: 31615585
Drug: Prucalopride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (1 mg)
Study: 25410983
Drug: ALA-mediated PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-mediated PDT (20% ALA solution, 1.5 h incubation, 630 nm red light, 80 J/cm(2))
Study: 19858394
Drug: VMP (bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMP (bortezomib 1.3 mg/m², melphalan 9 mg/m², prednisone 60 mg/m²)
Study: 11712719
Drug: Single-session music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session music therapy interventions
Study: 12787301
Drug: Montelukast 5
Normalized name: montelukast 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5 mg
Study: 9024176
Drug: Montelukast 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 20 mg
Study: 9039239
Drug: Montelukast 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 100 mg
Study: 9039239
Drug: Montelukast 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 250 mg
Study: 15332389
Drug: Montelukast 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 40 mg
Study: 9024176
Drug: Montelukast 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 200 mg
Study: 3722374
Drug: Frigid air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frigid air inhalation during exercise
Study: 10529124
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A 2.5 mg/kg/day
Study: 10529124
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A 1.5 mg/kg/day
Study: 29493047
Drug: Epirubicin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin treatment group
Study: 15886860
Drug: Coca Cola
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coca Cola (2.5 l per day)
Study: 15886860
Drug: Semi-skimmed milk
Normalized name: Calcium fortified semi-skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-skimmed milk (2.5 l per day)
Study: 11803087
Drug: Cell culture-derived
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell culture-derived vaccine
Study: 9240689
Drug: Egg-derived vaccine
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg-derived vaccine
Study: 10404100
Drug: PSA >/=
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA >/= 3 ng/ml as a direct biopsy indicator
Study: 10404100
Drug: PSA <
Normalized name: Prostate-Specific Antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA < 4 ng/ml with DRE and TRUS
Study: 10404100
Drug: Logistic-regression model
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Logistic-regression model predicting cancers for PSA < 4 ng/ml
Study: 7587256
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 0.037 g/kg bolus followed by 0.025 g/kg/hr infusion
Study: 7587256
Drug: Amiodarone 5
Normalized name: amiodarone 50 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 5 mg/kg bolus and 10 mg/kg/24-hr infusion
Study: 6249047
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose (experiment A)
Study: 30358116
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg + Dutasteride 0.5 mg + Imidafenacin 0.2 mg (TDI)
Study: 29352704
Drug: High-dose E1224
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose E1224 (4000 mg over 8 weeks)
Study: 29352704
Drug: Low-dose E1224
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose E1224 (2000 mg over 8 weeks)
Study: 29352704
Drug: Short-dose E1224
Normalized name: short ragweed pollen extracts
DrugBank: Ambrosia artemisiifolia pollen (DB10385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-dose E1224 (2400 mg over 4 weeks + 4 weeks placebo)
Study: 29352704
Drug: Benznidazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole (5 mg/kg per day for 60 days)
Study: 29352704
Drug: Placebo (E1224-matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (E1224-matched tablets for 8 weeks)
Study: 22301195
Drug: Citalopram (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (target dose of 30 mg/d)
Study: 9015133
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus dose of 5 mg Cr(VI)/L in drinking water (0.5 L swallowed in 2 min)